Title : A pilot, randomized, open-label trial assessing safety and pharmakokinetic parameters of co-administration of rivastigmine with risperidone in dementia patients with behavioral disturbances - Weiser_2002_Int.J.Geriatr.Psychiatry_17_343 |
Author(s) : Weiser M , Rotmensch HH , Korczyn AD , Hartman R , Cicin-Sain A , Anand R |
Ref : Int J Geriatr Psychiatry , 17 :343 , 2002 |
Abstract :
BACKGROUND: The majority of patients with Alzheimer's disease (AD) or vascular dementia display, in addition to cognitive impairment, various degrees of behavioral disturbances. As the use of cholinesterase inhibitors for the treatment of cognitive impairment in dementia becomes widespread, many of these patients will be treated concomitantly with cholinesterase inhibitors and with anti-psychotic drugs to ameliorate behavioral disturbances. Despite the widespread use of this combination in clinical practice, the safety and tolerability of such combination therapy has not been evaluated in controlled clinical trials. This pilot study examined the effects of addition of risperidone 0.5-2 mg/day to patients on rivastigmine 3-12 mg/day, and vice versa. |
PubMedSearch : Weiser_2002_Int.J.Geriatr.Psychiatry_17_343 |
PubMedID: 11994888 |
Weiser M, Rotmensch HH, Korczyn AD, Hartman R, Cicin-Sain A, Anand R (2002)
A pilot, randomized, open-label trial assessing safety and pharmakokinetic parameters of co-administration of rivastigmine with risperidone in dementia patients with behavioral disturbances
Int J Geriatr Psychiatry
17 :343
Weiser M, Rotmensch HH, Korczyn AD, Hartman R, Cicin-Sain A, Anand R (2002)
Int J Geriatr Psychiatry
17 :343